NCT07225166已完成不适用
A Clinical Investigation Into the Association of an Impaired Skin Barrier and Infant and Toddler Sensitive Skin
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Corneometer measurement results
研究概览
简要总结
This is a Single center, evaluator-blinded clinical trial that intends to • Evaluate differences in TEWL measurements between parent-reported sensitive skin subjects and healthy subjects (subjects without sensitive skin) • Evaluate differences in skin capacitance between parent-reported sensitive skin subjects and healthy subjects (subjects without sensitive skin). A sufficient number of subjects pairs (comprised of a parent subject and a child subject) will be enrolled to complete the study with at least 60 subject pairs (30 subject pairs per group).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 3 Months 至 36 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject pairs must meet all the following inclusion criteria for enrollment into the study (only one eligible child subject may be enrolled with any one parent subject).
- •Parent subject and child subject:
- •Generally, in good health based on medical history reported by the parent subject.
- •Intends to complete the study and is willing and able to follow the subject responsibilities and undergo necessary testing procedures (tape stripping for baby subjects) and answer multiple questionnaires.
- •Child subject:
- •Males and females aged 3 months-old up to 36 months-old (inclusive), targeting to complete with:
- •Sensitive Skin Cohort (cohort 1): at least 30 child subjects in the 3 months-old up to 36 months-old range with 100% HCP diagnosed sensitive skin or parent-reported sensitive skin, and as defined as parent subjects who respond "Yes" to the Yes/No question "Do you believe your child has sensitive skin?"
- •Non-Sensitive Skin Cohort (cohort 2): at least 30 child subjects in the 3 months-old up to 36 months-old age range with 100% having normal skin, has never been diagnosed with sensitive skin by a HCP, and as defined as parent subjects who respond "No" to the Yes/No question "Do you believe your child has sensitive skin?"
- •Has parent-reported natural skin tone "pale/fair to light white," "white to light beige," "beige to light tan/light olive," "medium tan/medium olive to light brown," "medium brown to dark brown," "darkest brown to darkest black", with every effort made to complete with at least 1 child subject for each skin tone per cohort.
- •Parent subject:
- •Is at least 18 years old.
- •Is the primary caregiver and legal guardian of the child subject and is willing and able to present proof of legal guardianship (e.g. birth certificate/hospital discharge paperwork along with valid ID of legal guardian, etc.).
- •Is able to read, write, speak, and understand English.
- •Has signed the Consent for Photo Release and ICD including a Health Insurance Portability and Accountability Act (HIPAA) disclosure.
- •Intends to complete the study and is willing and able to follow all study instructions.
- •Parent subjects must agree to discontinue child's current face/body washes and face/body lotions for 24 hours prior to their study visit.
排除标准
- •Child Subject:
- •Is using Systemic or topical over-the-counter (OTC) or prescription medications that, in the Investigator's judgement, will affect skin condition or interfere with study evaluation. (Use of acetaminophen as needed is acceptable if it was instructed by the baby's pediatrician. Child vitamins are allowed.)
- •Is using topical steroids within 2 weeks before Visit
- •Has Type 1 or Type 2 diabetes(reported by the parent) or is taking insulin or another anti-diabetic medication.
- •Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including:
- •Immunosuppressive or steroidal drugs within 2 months before Visit 1
- •Non-steroidal anti-inflammatory drugs within 5 days before Visit 1
- •Antihistamines within 2 weeks before Visit 1
- •If an individual is taking one of these medication types, the individual is not considered eligible at screening. However, if a subject begins using one of these medications during the study, the Investigator should be consulted to consider the impact of the specific medication on subject safety and/or the study results.
- •Has a history of or a concurrent health/other condition/situation which may put the child subject at significant risk, confound the study results, or interfere significantly with the subject pair's participation in the study, as determined by the Investigator or designee.
- •Has a history of skin cancer.
- •Is simultaneously participating in another study involving product usage or skin sampling for the duration of the study or has participated in another study involving product usage or skin sampling within 14 days prior to Visit
- •Has used new facial and body products and/or brands two weeks prior to Visit
- •Is an immediate family member of the Investigator, Study Site, or Sponsor.
- •Presents with a skin condition that may confound the study results, increase risk to the subject, or influence the outcome of the study (e.g., psoriasis, eczema, atopic dermatitis, cutaneous xerosis, or active skin cancer), as determined by the Investigator or designee.
- •Parent subject:
- •Is simultaneously participating in another study.
- •Is an employee/contractor of the Study Site or Sponsor or immediate family member of the PI, Study Site, or Sponsor.
结局指标
主要结局
Corneometer measurement results
时间窗: Visit 1 (Day 0)
Higher values indicate greater hydration of the skin
Tewameter measurement results
时间窗: Visit 1 (Day 0)
Lower values reflect a reduced rate of water loss (improved skin barrier function)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Efficacy of Investigational OTC Eye DropsOphthalmic SolutionsNCT03198000Johnson & Johnson Consumer Inc. (J&JCI)120
未知
4 期
A clinical trial to study the efficacy of steroids versus steroids and pentoxifylline in the treatment of patients with severe acute alcoholic hepatitisCTRI/2009/091/000876Dr Sandeep Sidhu ProfessorDepartment of GastroenterologyDMC and Hospital, Ludhiana. PunjabTel: 0161- 2402855 Cell: 9814025085, Fax: 0161-2302620Email- dmcgastro@in.com70
已完成
2 期
Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.Acute Respiratory Viral InfectionsHuman InfluenzaNCT04682444Joint Stock Company "Farmak"100
已完成
3 期
Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal HypersensitivityDentin SensitivityNCT02832375GlaxoSmithKline242
暂停
不适用
Omnibond vs DermabondOsteoarthritisNCT05173519Center for Innovation and Research Organization310